Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Notice of Quarterly Shareholder Update Webinar

24 April 2025 – Melbourne, Australia: Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce that it will host a "Quarterly shareholder update webinar – Q3 FY2025".

The webinar will be hosted by Managing Director and Chief Executive Officer Dr Michael Thurn and will provide a comprehensive update on the Company's progress during the previous quarter, alongside key priorities for the months ahead. Shareholders will also have an opportunity to meet some of the Company's new executive leaders, who bring deep expertise in regulatory affairs, finance, and commercialisation.

Date & Time: Tuesday, May 6th, 2025 at 1 PM AEST
Register at: https://bit.ly/NeurizonQ325

During the session, the Neurizon® leadership team will discuss:

- Advancements made toward participation in the HEALEY ALS Platform Trial
- Regulatory engagement with the FDA and an update on the NUZ-001 IND clinical hold
- Participation in key industry events and advocacy initiatives, and expanding awareness of MND/ALS and Neurizon's mission
- Recent executive appointments and how Neurizon's growing leadership team is helping drive development and commercial strategy
- An outlook on upcoming milestones in advancing NUZ-001 through late-stage development

Attendees are encouraged to submit their questions in advance, either during the registration process or by emailing enquiries@neurizon.com.

A recording of the webinar will be available on Neurizon's website after its completion.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:

Dr. Michael Thurn
Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

Lidija Damjanovic
Head of Marketing and Corporate Affairs
Neurizon Therapeutics Limited
lidija@neurizon.com
+61 (0) 425 700 504

Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited.